Advertisement

Organisation › Details
Tacalyx GmbH
Tacalyx is a privately held biotech company focused on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. TACAs are formed during malignant transformation in a microevolutionary process. The expression of TACAs is elevated in many cancer cell types which makes them attractive potential targets for cancer treatment by harnessing and directing the natural immune response. Tacalyx is developing its proprietary technology platform to exploit TACAs as novel targets for antibody-based therapies, including antibody-drug conjugates (ADCs) and other modalities, and has established a proprietary pipeline with seven independent projects. Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, based on work of Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz. Tacalyx is headquartered in Berlin, Germany and is backed by leading European life sciences and technology investors Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, High-Tech Gründerfonds (HTGF), coparion, Eurazeo/Idinvest Partners, Creathor Ventures, and Thuja Capital. *
![]() |
Start | 2019-07-04 established (s-off) |
Predecessor | Max Planck Institute of Colloids and Interfaces (Potsdam-Golm) | |
![]() |
Industry | TACA antibody |
Industry 2 | plaQorm discovery platform | |
![]() |
Person | Sondermann, Peter (Tacalyx 201909 CEO before Shire + Baxalta + SuppreMol + Roche + Glycart Biotechnology) |
Person 2 | Seeberger, Peter H. (MPI of Colloids and Interfaces 2009– Director before ETH Zurich Prof before MIT Prof) | |
![]() |
Region | Berlin |
Country | Germany | |
Street | 11 Magnusstr. 3th Floor | |
City | 12489 Berlin | |
Tel | +49-30-407237-10 | |
Address record changed: 2023-11-11 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Tacalyx GmbH. (6/11/24). "Press Release: Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs". Berlin. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Tacalyx GmbH
- [1] Tacalyx GmbH. (6/11/24). "Press Release: Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs". Berlin....
- [2] Tacalyx GmbH. (9/25/19). "Press Release: Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top